Share

April 02, 2019; 92 (14) Editorial

Dietary patterns in early life pay dividends for midlife cognitive performance

Gene L. Bowman, Nikolaos Scarmeas
First published March 6, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007229
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
97

Share

Article Information

vol. 92 no. 14 645-646
DOI: 
https://doi.org/10.1212/WNL.0000000000007229
PubMed: 
30842297
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published March 6, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Gene L. Bowman, ND, MPH and
    2. Nikolaos Scarmeas, MD, PhD
  1. Gene L. Bowman, ND, MPH and
    2. Scientific Advisory Boards:

    1. an unpaid scientific advisor of the Horizon 2020 European Union-funded PROPAG-AGEING project, whose aim is to identify novel biomarkers for earlier diagnosis of Parkinson disease https://www.propag-ageing.eu/consortium/advisory- board/scientific-advisory-board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease, Associate Editor (2009-16)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH/NIA, RO1 AG043398, Grant PI, Current Co-PI, 2014-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Nikolaos Scarmeas, MD, PhD
    3. Scientific Advisory Boards:

    1. (1)Commercial entity: Participation at a single advisory board meeting for Merck Consumer Health (2)Non-profit entity (Albert Einstein College of Medicine): Data Safety Monitoring Board chair for an NIH funded clinical trial.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Commercial entity Eisai - patient recruiting site at a phase III clinical trial of a BACE inhibitor for Alzheimer's Disease ? unrelated to the submitted work.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Marcus Institute for Aging Research (G.L.B.), Hebrew SeniorLife; Department of Medicine (G.L.B.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; Department of Neurology (G.L.B.), Oregon Health & Science University, Portland; Department of Social Medicine, Psychiatry and Neurology (N.S.), National and Kapodistrian University of Athens; 1st Neurology Clinic (N.S.), Aeginition Hospital, Athens, Greece; and Taub Institute for Research in Alzheimer's Disease and the Aging Brain (N.S.), Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, NY.
  1. Correspondence
    Dr. Bowman genebowman{at}hsl.harvard.edu
View Full Text

Article usage

Article usage: March 2019 to August 2019

AbstractFullPdfSource
Mar 20191546241Highwire
Apr 20195024836Highwire
May 2019121125Highwire
Jun 201916339Highwire
Jul 20199223Highwire
Aug 201911213Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me